Fourteen weeks of liraglutide therapy in subjects with type 2 diabetes significantly improves first phase insulin secretion and maximal beta-cell secretory capacity

被引：0
|
作者：
Madsbad, S.
Brock, B.
Perrild, H.
Lervang, H. H.
Kolendorf, K.
Krarup, T.
Schmitz, O.
Le-Thi, T.
Zdravkovic, M.
Vilsboll, T.
机构：
[1] Hvidovre Univ Hosp, DK-2650 Hvidovre, Denmark
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Bispebjerg Univ Hosp, Copenhagen, Denmark
[4] Aarhus Univ Hosp, Aalborg, Denmark
[5] Roskilde Cty Psychiat Hosp Fjorden, Roskilde, Denmark
[6] Gentofte Univ Hosp, Hellerup, Denmark
[7] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0004
引用
收藏
页码：4 / 5
页数：2
相关论文
共 50 条
  • [41] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan
    Duffin, Kevin
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : 388 - 396
  • [42] Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes
    Pennartz, Christian
    Schenker, Nina
    Menge, Bjorn A.
    Schmidt, Wolfgang E.
    Nauck, Michael A.
    Meier, Juris J.
    DIABETES CARE, 2011, 34 (09) : 2048 - 2053
  • [43] Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
    Fehse, F
    Trautmann, M
    Holst, JJ
    Halseth, AE
    Nanayakkara, N
    Nielsen, LL
    Fineman, MS
    Kim, DD
    Nauck, MA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11): : 5991 - 5997
  • [44] Insulin therapy for type 2 diabetes: Rescue, augmentation, and replacement of beta-cell function (vol 70, pg 489, 2004)
    Mayfield, JA
    White, RD
    AMERICAN FAMILY PHYSICIAN, 2004, 70 (11) : 2079 - 2080
  • [45] Relationship of obesity with glucose and beta-cell secretion during a standard meal in newly diagnosed treatment naive subjects with type 2 diabetes mellitus
    Luzio, S
    Peter, R
    Dunseath, G
    Mustafa, N
    Pauvaday, V
    Owens, DR
    DIABETES, 2005, 54 : A448 - A448
  • [46] Cutting the brakes to prevent Type 2 Diabetes onset: augmenting insulin secretion and conserving pancreatic beta-cell mass by deleting Gαz
    Wisinski, Jaclyn
    Reuter, Austin
    Kimple, Michelle
    FASEB JOURNAL, 2017, 31
  • [47] Dietary and genetic control of pancreatic beta-cell glucose transporter glycosylation promotes insulin secretion in suppressing the pathogenesis of type-2 diabetes
    Ohtsubo, Kazuaki
    Takamatsu, Shinji
    Marth, Jamey D.
    GLYCOBIOLOGY, 2006, 16 (11) : 1116 - 1116
  • [48] Determinants of Reversibility of Beta-Cell Dysfunction in Response to Short-Term Intensive Insulin Therapy in Patients With Early Type 2 Diabetes
    Kramer, Caroline K.
    Choi, Haysook
    Zinman, Bernard
    Retnakaran, Ravi
    DIABETES, 2013, 62 : A243 - A243
  • [49] Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study
    Hompesch, Marcus
    Kang, Jahoon
    Han, OakPil
    Trautmann, Michael E.
    Sorli, Christopher H.
    Ogbaa, Ike
    Stewart, John
    Morrow, Linda
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [50] Beta cell dysfunction in IGT and early type 2 diabetes: comparison of surrogate markers with first phase insulin secretion from an intravenous glucose tolerance test
    Festa, A.
    Haffner, S. M.
    Williams, K.
    DIABETOLOGIA, 2006, 49 : 379 - 380
12345